Perpetual LTD Bristol Myers Squibb CO Transaction History

Perpetual LTD

$9.23 Trillion
Q3 2024

A detailed history of Perpetual LTD transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Perpetual LTD holds 24,209 shares of BMY stock, worth $1.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

24,209

Previous 22,966 5.41%

Holding current value

$1.4 Million

Previous $954 Million 31.33%

% of portfolio

0.01%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 09, 2024	BUY	$39.66 - $51.75 $49,297 - $64,325	1,243 Added 5.41%	24,209 $1.25 Billion
Q2 2024 Jul 30, 2024	SELL	$40.25 - $52.99 $346,150 - $455,714	-8,600 Reduced 27.24%	22,966 $954 Million
Q1 2024 Apr 09, 2024	BUY	$47.98 - $54.4 $588,522 - $667,270	12,266 Added 63.55%	31,566 $1.71 Billion
Q4 2023 Feb 15, 2024	SELL	$48.48 - $57.85 $454,354 - $542,170	-9,372 Reduced 32.69%	19,300 $990 Million
Q3 2023 Oct 10, 2023	BUY	$57.89 - $64.73 $965,836 - $1.08 Million	16,684 Added 139.17%	28,672 $1.66 Billion
Q1 2023 May 08, 2023	SELL	$65.71 - $74.53 $286,232 - $324,652	-4,356 Reduced 26.65%	11,988 $831 Million
Q2 2020 Nov 18, 2020	BUY	$54.82 - $64.09 $895,978 - $1.05 Million	16,344 New	16,344 $2.03 Million
Q1 2020 Nov 18, 2020	SELL	$46.4 - $67.43 $758,361 - $1.1 Million	-16,344 Closed	0 $0
Q2 2019 Jul 30, 2019	SELL	$44.62 - $49.34 $80,316 - $88,812	-1,800 Reduced 9.92%	16,344 $741,000
Q2 2018 Jul 23, 2018	BUY	$50.53 - $62.98 $916,816 - $1.14 Million	18,144 New	18,144 $1.01 Million

Others Institutions Holding BMY

# of Institutions

2,536

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $123B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Perpetual LTD, based on Form 13F filings with the SEC.

News

Stay updated on Perpetual LTD with notifications on news.

Account